(OP:NUMIF)

0.0163 -0.0037 (-18.50%)

Delayed Quote Updated: 3:26 PM EDT, Oct 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about NUMIF

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

American Billionaire Entrepreneurs Bet Millions on Psychedelics

May 10, 2022

FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – May 10, 2022 – Billionaire Bob Parsons, the founder of GoDaddy, believes psychedelics can heal trauma. The Marine infantryman...

Via FinancialNewsMedia

Novamind To Offer Virtual Mental Health Therapy Sessions ↗

May 02, 2022

Novamind (OTCQB: NVMDF), which is to be acquired by Numinus Wellness (OTCMKTS: NUMIF), recently announced a collaboration with health coaching platform HealCommunit

Via Benzinga

Roth Capital Reveals Top Psychedelic Picks in New Industry Report

April 21, 2022

FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – April 21, 2022 – Investment banks are continuing to release positive coverage for psychedelic stocks and the latest report...

Via FinancialNewsMedia

Numinus to Acquire Novamind For $20.74M In Stock ↗

April 12, 2022

Via Benzinga

Numinus Wellness Strives To Become Psychedelic Research Hub After Acquisition Of Novamind Inc. ↗

April 13, 2022

In a year where M&A activity is expected to ratchet-up in 2022, Numinus Wellness Inc. (OTC: NUMIF) is among the first to take action.

Via Benzinga

Psyched: Atai, MindMed, Enveric and Mydecine Release 2021 Earnings, Bienstar Expands To Brazil & More! ↗

April 06, 2022

It’s earnings week in the psychedelics space, opening a new window into the financial situations of many companies in the sector.

Via Benzinga

March Update: Psychedelic Compounds-Based Drug Stocks Index Went Down -19% ↗

April 01, 2022

An update on the revisions that have been made to the Pure-Play Psychedelic Compounds-Based Drug Stocks Index with the increase in the minimum market capitalization required to be included in the...

Via Talk Markets

Numinus Administers MDMA To First Volunteer In Clinical Trial Sponsored By MAPS ↗

March 30, 2022

Numinus Wellness Inc. (OTCQX: NUMIF), announced that clinical trial MAPPUSX has gotten underwaywith the enrolling and dosing ...

Via Benzinga

Demand for Toad Venom Rises Along With the Booming Psychedelics Market

March 30, 2022

FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – March 30, 2022 – Depression and anxiety affect millions around the world and the venom of a toad is the latest psychedelic...

Via FinancialNewsMedia

Psychedelic Compounds-Based Drug Stocks Down Slightly This Past Week ↗

March 27, 2022

We're tracking 13 public companies (US and/or Canada) doing clinical-stage research into THC and/or psychedelics for treating mental illnesses. While a few were up this week, the overall trend...

Via Talk Markets

Cannabis Movers & Shakers: TGOD, Numinus Wellness, GTI, Neptune Wellness ↗

February 18, 2022

The Green Organic Dutchman Names New CFO The Green Organic Dutchman Holdings Ltd. (CSE:

Via Benzinga

Benzinga's Unprecedented Psychedelics Investing Conference Lands In Miami On April 19th ↗

February 09, 2022

The first Benzinga Psychedelics Capital Conference, the premier gathering of psychedelics industry leaders and forward-thinking investors, is coming to the Fontainebleau Miami Beach on April 19, 2022,...

Via Benzinga

Psyched: Psychedelics ETF Launches On NYSE, Psilocybin Trial Approved For Depression, DMT Study Begins ↗

February 07, 2022

This week saw new triumphs for public companies in the psychedelics space with the creation of a new ETF tracking the sector, which went public in the NYSE.

Via Benzinga

Psychedelic Stocks Finally In An Upswing ↗

February 06, 2022

The Marijuana & Psychedelic Compounds-Based Drug Stocks Index went up +5.3% last week.

Via Talk Markets

Psychedelics Co. Numinus Wellness Appoints New Bioscience Advisors To Bolster IP Development ↗

February 01, 2022

Psychedelics-focused company Numinus Wellness Inc. (TSX:NUMI) (OTCQX: NUMIF) announced the appointment of three key advisors to its new Bioscience Advisory Board.

Via Benzinga

The Psychedelic & Marijuana Drug Stocks Index Dropped -30% In January ↗

January 30, 2022

This article updates the performances of 16 clinical-stage psychedelic and marijuana drug companies researching the treatment of a wide variety of mental illnesses.

Via Talk Markets

Psyched: Eleusis To Go Public Via Merger, New Psychedelics Bills In Utah, Virginia, Kansas And Missouri ↗

January 24, 2022

Psychedelics Legalization Gains Momentum Around The Country: Bills Introduced In Utah, Virginia, Kansas And Missouri A wave of psychede...

Via Benzinga

Weekend Update: Only 2 Psychedelic Drug Stocks Are Up YTD ↗

January 23, 2022

This article updates the performances of the 16 largest capitalized clinical-stage psychedelic and marijuana drug companies researching the treatment of a wide variety of mental illnesses out of a...

Via Talk Markets

Numinus Wellness Reveals 244.5% YoY Improvement In Q1 Revenue & Wider Loss ↗

January 21, 2022

Numinus Wellness Inc (TSX:NUMI) (OTC:

Via Benzinga

Psilocybin and MDMA Get the Green Light for Medical Use in Canada

January 19, 2022

FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – January 19, 2022 – After facing legal scrutiny for decades, psychedelics including MDMA and psilocybin received a stamp of...

Via FinancialNewsMedia

Marijuana & Psychedelic Drug Stocks Continue To Decline ↗

January 16, 2022

The Marijuana & Psychedelic Compounds-Based Drug Stocks Index consists of 16 of the 100 such companies that trade on North American stock exchanges. 5 of them are marijuana drug stocks and 11 are...

Via Talk Markets

Pure-Play Marijuana- & Psychedelic Compounds-Based Drug Stocks Index Is Down By 66% From 2021 High ↗

January 09, 2022

There are 16 remaining constituents of our Marijuana & Psychedelic Compounds-Based Drug Stocks Index is now DOWN -65.9% from its highs in 2021. Here are the details for each of its constituents.

Via Talk Markets

Steep Decline In Cannabis & Psychedelic Compounds-Based Drug Stocks Continues: DOWN -16.6% MTD ↗

December 24, 2021

All 12 constituents in the Marijuana & Psychedelic Compounds-Based Drug Stocks Index continue to decline. How do their performances compare month-to-date and YTD?

Via Talk Markets

The Year In Review For Psychedelic Drug Stocks: 2021 ↗

December 21, 2021

2021 was two different

Via Talk Markets

Why Some Psychedelic Assisted Therapy Clinics Are Turning To Artificial Intelligence for Digital Mental Therapies

December 16, 2021

Palm Beach, FL –December 16, 2021 – FinancialNewsMedia.com News Commentary – Drugs like ketamine and psilocybin — the active ingredient in magic mushrooms — are showing real promise in addressing...

Via FinancialNewsMedia

Topics Artificial Intelligence

Psychedelics Company Numinus Wellness Q4 Revenue Grows 81% YoY Thanks To Mindscape Acquisition ↗

December 10, 2021

Psychedelics-focused mental health care company Numinus Wellness Inc. (TSXV:

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.